---
title: "Curative Biotechnology, Inc. (CUBT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CUBT.US.md"
symbol: "CUBT.US"
name: "Curative Biotechnology, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T09:58:38.509Z"
locales:
  - [en](https://longbridge.com/en/quote/CUBT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CUBT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CUBT.US.md)
---

# Curative Biotechnology, Inc. (CUBT.US)

## Company Overview

Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine; and development agreement with the University of Pennsylvania School of Veterinary Medicine for the development of a metformin-based ophthalmic formulation.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [curativebiotech.com](https://curativebiotech.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.03 | 352 | - | - | - |
| PB | -1.95 | 491 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CUBT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CUBT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CUBT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CUBT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**